Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results

BACKGROUND: In an attempt to improve low density lipoprotein-cholesterol (LDL-C) level control in patients ineffectively treated with statins, we evaluated the effectiveness of a fixed-dose combination (FDC) of 10 mg rosuvastatin and ezetimibe and its relation to the timing of drug administration. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Obońska, Karolina, Kasprzak, Michał, Tymosiak, Kamila, Fabiszak, Tomasz, Krintus, Magdalena, Kubica, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2021
Materias:
Clinical Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105047/
https://www.ncbi.nlm.nih.gov/pubmed/33200812
http://dx.doi.org/10.5603/CJ.a2020.0166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105047/
https://www.ncbi.nlm.nih.gov/pubmed/33200812
http://dx.doi.org/10.5603/CJ.a2020.0166

Ejemplares similares